Dr. Sattva S Neelapu is tenured Professor and Deputy Chair in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, Houston, Texas. He completed medical school in India, Internal Medicine residency in New York, and clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute, Bethesda, Maryland. As a physician-scientist at MD Anderson, his research is focused on clinical and translational development of novel immunotherapies for B-cell malignancies. His work on the pivotal clinical trial of axicabtagene ciloleucel CD19 CAR T-cell therapy in aggressive B-cell lymphomas led to its FDA approval as the first CAR T-cell therapy for lymphoma. Dr. Neelapu has authored or co-authored over 200 publications. He is nationally and internationally recognized for his expertise in CAR T-cell therapy in lymphomas and management of toxicities associated with CAR T-cell therapy.